joining the dots of recent obj announcements, page-7

PS - I forgot to add:

The best about thing OBJ is its core business model - all its major R & D
has been/is being been paid for by its big pharma partners, such as companies like GSK and Reckitt Benckiser.

This is a huge cost NOT to have - yet OBJ WILL STILL GETS ROYALTIES when these new &/or re-developed (ie-Nurofen) GLOBAL PRODUCTS hit the market... and those royalties will be considerable.

(Plus the marketing costs will be paid for our partners.)

I find this business strategy brilliant. It greatly protects this small 2c company as it expands in these times of financial uncertainty.